Module 3:​ Clinical Trials in Hyperphosphatemia Management

Primary Audience:

This activity is intended to meet the educational needs of nephrologists, advanced practice providers (APPs), nurses, dietitians, pharmacists, and other healthcare professionals involved in managing hyperphosphatemia in CKD patients requiring dialysis.

This module will begin with evidence for the recently approved tenapanor for hyperphosphatemia. This will encompass three trials leading to its approval. Then, we will cover evidence for more recently approved phosphate binders individually.

Mo Atta, MD

Professor of Medicine
Department of Nephrology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mohamed G. Atta, MD, MPH, is Professor of Medicine at Johns Hopkins University School of Medicine in Baltimore, Maryland and Director of Von Hippel Lindau Clinical Care Center at Hopkins. A graduate of Mansoura University School of Medicine in Egypt, he completed his internship and residency training in various locations including the Urology and Nephrology Center at Mansoura University, Cabrini Medical Center in New York, and Johns Hopkins University School of Medicine. Dr. Atta received his MPH degree from Johns Hopkins Bloomberg School of Public Health in 2005.

Dr. Atta is a member of the Health Disparity Committee at the Department of Health and Mental Hygiene in Maryland, the Scientific Council on Kidney of the American Heart Association, the International Society of Nephrology, and the American Society of Nephrology. Dr. Atta has participated as principal investigator in several studies, clinical trials, and serves as a peer reviewer for the Journal of Clinical Investigation, Archives of Internal Medicine, American Journal of Medicine, Kidney International, Journal of the American Society of Nephrology, Clinical Journal of the American Society of Nephrology, American Journal of Kidney Diseases, Clinical Infectious Disease, and Journal of Infectious Diseases among others. He authored or co-authored numerous articles published in Genomics, the Journal of Biological Chemistry, Journal of clinical investigation, Clinical Infectious Disease, Circulation, Stem Cells Translational Medicine, American Journal of Medicine, and American Journal of Transplantation, Journal of the American Society of Nephrology, Clinical Journal of the American Society of Nephrology, American Journal of Kidney Disease, Nephrology Dialysis Transplantation, and Kidney International, among others.

1.
Incorporate the most current clinical trial evidence to effectively treat hyperphosphatemia in patients on dialysis.